M2 Archive: Preview


You haven't logged in. If you have archive credits in your account, please log in now to use them. If not, you can buy credits in our shopping area.


Imfinzi granted US Orphan Drug Designation for small cell lung cancer

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Imfinzi (durvalumab) for the treatment of small cell lung cancer (SCLC).

SCLC constitutes about 15% of all lung cancer diagnoses. It is the most aggressive type of lung...  


If you want to view the full text of this story, you must first purchase archive credits. Return to Archives
New Search